VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian healthcare company, announces the closing of the second tranche (the "Second Tranche") of its non-brokered private placement (the "Offering"), previously announced on November 6, 2025, with the first tranche closed on November 14, 2025. Gross proceeds from the Second Tranche totaled CAD $210,000 from the sale of 3,000,000 units (the "Units") at an issue price of CAD $0.07 per Unit.
The Company did not pay any cash finder's fees pertaining to the Second Tranche of the Offering.
The Company will use the proceeds of the Offering towards advancing its Alzheimer's Disease ("AD") program including the opening of its first U.S. AD clinic, general and administrative expenses and for working capital purposes.
The securities issued and issuable, described in this and the previous news release on November 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.
The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or ...
